r/valueinvesting
McKesson Deep-Dive ($MCK): A 20% Panic, and a Structural Margin of Safety
MCK's 20% drop is a buying opportunity due to its oligopoly moat, aggressive buybacks, and pivot to high-margin oncology.
- Rational oligopoly moat with high customer switching costs in pharmaceutical distribution.
- Asset-light model generating strong FCF, paired with aggressive share buybacks reducing share count by over 60% in 20 years.
- Strategic pivot to higher-margin oncology and multi-specialty segments while divesting low-margin assets.
Hey everyone,
I wanted to share a quick fundamental thesis on McKesson Corporation ($MCK) following its recent \~20% correction from its peak. I've pasted the link at the bottom of this post for anyone who wants to read more in-depth. The stock dropped from nearly $1,000 down to around $740, primarily driven by a top-line revenue miss in Q4 of fiscal 2026. However, looking under the hood, the structural thesis for this long-term compounder remains incredibly intact.
Here are the key pillars of the value thesis:
- A Rational Oligopoly Moat
McKesson, along with Cencora and Cardinal Health, control a vast majority of the U.S. pharmaceutical distribution market. Their value proposition to hospital networks and pharmacies is absolute supply chain reliability and working capital optimization. A community pharmacy cannot afford to hold millions of dollars of inventory on its balance sheet; McKesson handles the logistics, creating massive customer switching costs.
- Asset-Light Capital Allocation & Cannibalization
Despite operating on razor-thin margins (roughly 1.5% operating margins), MCK is an incredibly capital-light business model that generated $5.4 billion in free cash flow in FY 2026. Management's capital allocation strategy is perfectly aligned with shareholders, with compensation tied directly to ROIC and Adjusted EPS. Rather than empire-building via low-return projects, they aggressively buy back stock. Over the last 20 years, McKesson has reduced its outstanding share count by over 60%, creating a permanent tailwind for per-share metrics.
- Higher-Margin Segment Pivot
The market is treating MCK like a stagnant legacy distributor, but management is aggressively shedding low-margin, non-core assets (like their recent European divestitures and selling Rexall/Well.ca). They are pivoting capital into their Oncology and Multi-Specialty segment, which grew revenues by 31% and operating profit by 53% in FY 2026. This segment boasts double the operating margins (2.27%) of their core pharmaceutical distribution business.
- The Valuation & Margin of Safety
Using highly conservative assumptions where growth completely stagnates over the next four years, drops to 2% in year four, and hits 0% by year five with a 0% terminal growth rate, my DCF model places McKesson's conservative intrinsic value at $885 a share (an 18% upside to a worst-case scenario).
If you adjust the terminal growth rate to a more realistic, albeit still very conservative, 2% (in line with long-term inflation targets), the intrinsic value jumps to $1,275 per share, representing a 70% upside.
Summary:
• Tailwinds: Structural demand from an aging U.S. demographic and massive volume acceleration from GLP-1 agonists.
• ROIC: Reached a colossal 70% last year.
• Shareholder Returns: The board just approved a fresh $5B share buyback program at the end of Q4.
I'd love to hear your thoughts on the competitive dynamics against Cardinal/Cencora and whether you think the recent top-line miss is structural or just temporary noise.
If you want to read the full breakdown, or dive more deeply into this name, you can read my full deep-dive here: https://mulberryfinancial.substack.com/p/mckesson-mck-stock-analysis-deep-dive-2026?r=4af6n2
I held Cencora back when it was still AmerisourceBergen for a couple years, and the thing that finally clicked is that the revenue line on these is basically theater. They run on roughly 1% operating margins, so a headline beat or miss on sales tells you almost nothing. What actually moved the stock every quarter was segment operating profit and whether a big pharmacy contract was coming up for renewal. Once I stopped reacting to the topline, the whole sector got a lot easier to sit through drops like this 20% one.
Great point, thanks for the insight.
I’m looking to make an entry in Cencora, any recommendations if this is a good or bad idea? I like the price from its all time
Highs.
This is a business model that can evaporate at any moment, literally with the stroke of a pen. I’m heavily in favour of pharma when it comes to the drug price ‘issue’ and I believe their arguments against the big PBMs are much more convincing, and politicians are far more receptive to such arguments than those coming out the managed care/PBM lobby base
Respectfully, it is not true that this business model could evaporate at any moment, literally with the stroke of a pen. I spoke with numerous pharmacy professionals while writing this, and all I took awqy from those meetings is that it would be very, very difficult, if not impossible, for this business model to "evaporate".
The opioid litigation against all 3 companies has been settled. Agree with you that the business model can’t just evaporate. Thank You for the worst case scenario terminal growth information. I see cardinal health investors rotating into McKesson because CAH is at an all time high right now.
Great points. I have held mck for years. Buying as much as I can in the $750 range
The top-line miss being treated as structural is the part that gets me. When your business model is built around pharmaceutical volume throughput and an aging population, a single quarter's revenue shortfall looks a lot more like procurement timing or formulary shifts than any kind of demand destruction.
The oncology pivot is genuinely the most interesting piece of this thesis to me. 53% operating profit growth in that segment while the market is pricing it like a plain distributor is a weird disconnect. The margin differential between oncology and core distribution is small in absolute terms but the trajectory is what matters, and management seems to be allocating capital accordingly.
The 60% share count reduction over 20 years is the kind of stat that sounds boring until you actually model what that does to per-share earnings over a full cycle. Most people skip past it and anchor on total revenue or headline margins, which is exactly why the market keeps misreading capital-light compounders like this.
The ROIC at 70% is the number I'd push back on a little though. Not that it's wrong, but that level tends to attract regulatory scrutiny in healthcare distribution eventually, and the oligopoly structure has been on policy radar on and off for years. Worth keeping an eye on even if it's not an immediate risk.
Cardinal health and cencora missed badly on revenue last quarter also so it was an industry wide issue. What surprises me is how CAH went from a $181 low after earnings all the way to all time highs at $234 so fast. McKesson and cencora are more undervalued than CAH right now.
Great points thanks for the insight.